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A comprehensive understanding of the clonal evolution of cancer is critical for 
understanding neoplasia.  Genome-wide sequencing data enables evolutionary 
studies at unprecedented depth. However, classical phylogenetic methods 
often struggle with noisy sequencing data of impure DNA samples and fail to 
detect subclones that have different evolutionary trajectories. We have 
developed a tool, called Treeomics, that allows us to reconstruct the phylogeny 
of a cancer with commonly available sequencing technologies. Using Bayesian 
inference and Integer Linear Programming, robust phylogenies consistent 
with the biological processes underlying cancer evolution were obtained for 
pancreatic, ovarian, and prostate cancers. Furthermore, Treeomics correctly 
identified sequencing artifacts such as those resulting from low statistical 
power; nearly 7% of variants were misclassified by conventional statistical 
methods. These artifacts can skew phylogenies by creating illusory tumor 
heterogeneity among distinct samples. Importantly, we show that the 
evolutionary trees generated with Treeomics are mathematically optimal.   
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Genetic evolution underlies our current understanding of cancer1–3 and the 
development of resistance to therapies4–7. The principles governing this evolution are still 
an active area of research, particularly for metastasis, the final biological stage of cancer 
that is responsible for the vast majority of deaths from the disease. Although many 
insights into the nature of metastasis have emerged8,9, we do not yet know how malignant 
tumors evolve the potential to metastasize nor do we know the temporal or spatial rules 
governing the seeding of metastases at sites distant from the primary tumor10–13.  
 
In an effort to help understand this process, reconstructions of the temporal 
evolution of a patient's cancer from genome sequencing data have been reported14–17. But 
phylogenomic analysis has largely been focused on the subclonal structure and branching 
patterns of primary tumors18–20. The evolutionary relationships among metastases have 
less often been determined21–25, despite their importance. Several factors complicate the 
determination of the evolutionary histories of metastatic cancers. First, comprehensive 
data sets of samples from spatially-distinct metastases in different organs are rarely 
available. Second, most advanced cancer samples are derived from patients who have 
been treated with toxic and mutagenic chemotherapies, imposing a variety of unknown 
constraints on genetic evolution and its interpretation. Third, tumors are composed of 
varying proportions of neoplastic and non-neoplastic cells, and inferring meaningful 
evolutionary patterns from such impure samples is challenging26,27. Moreover, the 
situation for solid tumors differs from that of “liquid tumors”, where mutant allele 
fractions are high and can be easily determined from cytological analysis. Fourth, 
chromosome-level changes, including losses, are frequently observed in cancers, and 
previously acquired variants can be lost (i.e., some variants are not "persistent"). Finally, 
even when performed at high depth, next-generation sequencing coverage is always non-
uniform, resulting in different amounts of uncertainty among different loci within the 
same DNA sample as well as among different samples at the same locus. 
 
The variety of methods that have recently been used to infer evolutionary 
relationships among tumors underscore these complicating factors and the need for a 
more robust phylogenomic approach.  The methods include those based on genetic 
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distance23,28–30, maximum parsimony31,25, clonal ordering3,17,24 and variant allele 
frequency18,32,33. Classical phylogenetics assumes that the individual traits are known 
with certainty26. Consequently these methods struggle with noisy high-throughput DNA 
sequencing data, possibly from very impure samples, and fail to exploit the full potential 
of these data due to the error-prone binary present/absent classification of variants. 
Modern phylogenomic methods34–37 estimate variants from the observed variant allele 
frequencies (VAF). However, inaccurate VAFs resulting from insufficient sequencing 
depth or low sample purity introduce potential errors in the analysis. Furthermore, many 
of the methods used for inferring cancer evolutionary trees are based on those designed 
for more complex evolutionary processes involving sex and recombination12.  
  
Our current study was inspired by a different component of evolutionary biology, 
involving the analysis of asexual rather than sexual populations. One key conceptual 
difference between the new approach used here (“Treeomics”) and previous ones is that 
we determined the probability that each variant was or was not found in each sequenced 
lesion rather than rely on a binary input ("present" or "absent"), as used in classical 
phylogenetic methods. This evolutionary approach results in multiple advantages: (i) it is 
amenable to low coverage sequencing data and impure samples, (ii) no constraints on tree 
topologies, substitution models or mutation rates are required, (iii) Mixed Integer Linear 
Programming38 produces a single result without convergence or termination issues, and 
(iv) the obtained evolutionary tree is mathematically guaranteed to be optimal.  
 
RESULTS 
Evolutionarily incompatible mutation patterns 
To illustrate our approach, we first focused on the data of a treatment-naïve pancreatic 
cancer patient Pam0322 (Fig. 1). WGS (whole-genome sequencing; coverage: median 
51x, mean 56x) as well as deep targeted sequencing (coverage: median 296x, mean 644x) 
was performed on ten spatially-distinct samples from the primary tumor and distinct liver 
and lung metastases (Online Methods and ref. 22). Estimated purities ranged from 16% to 
43% per sample22, typical for low-cellularity cancers. Founder variants (present in all 
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samples) and unique variants (present in exactly one sample) are parsimony-
uninformative and hence irrelevant for the branching in an evolutionary tree. 
Parsimony-informative variants (variants present in some but not in all samples; depicted 
by black dots in Fig. 1) exhibited many evolutionary incompatibilities when we tried to 
reconstruct a phylogeny consistent with the evolutionary processes underlying tumor 
progression using conventional methods. In particular, evolutionary relationships could 
not be inferred based on standard present/absent classification of variants (Fig. S1).   
 
The mutation pattern of a variant is denoted by the set of samples where the variant 
is present (Fig. S1). Two somatic variants ! and ! are evolutionarily incompatible if and 
only if samples with the following three patterns exist: (i) variant ! is absent and ! is 
present, (ii) ! is present and ! is absent, and (iii) both variants are present. Because 
somatic variants are by definition absent in the germline, ! and ! are evolutionarily 
incompatible, so no perfect (the same variant is not independently acquired twice; infinite 
sites model39) and persistent (acquired variants are not lost; no back mutation) phylogeny 
can be inferred (Fig S1). 
 
  A perfect and persistent tree consistent with the observed (noisy) data of Pam03 
cannot be inferred and may not even exist40–42. Treeomics shows that such a phylogeny 
may indeed exist but that it is hidden behind technical and biological artifacts. Although 
the median coverage in the sequencing data from Pam03 was high, many of the identified 
variants had a coverage below 20x in at least one of the impure samples (purity <20%; 
Fig. S2), leading to potentially misleading evolutionary patterns with standard 
approaches, as shown below. 
 
Identifying evolutionarily compatible mutation patterns 
To account for inconclusive data, we developed a Bayesian inference model to calculate 
the probability that a variant is present in a sample (detailed in Online Methods). Using 
these probabilities for each individual variant, we calculated reliability scores for each 
possible mutation pattern. We constructed an evolutionary conflict graph where the nodes 
were determined through analysis of all mutation patterns, with the weights of each node 
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provided by the calculated reliability scores (Fig. S3). If two nodes (mutation patterns) 
were evolutionarily incompatible, an edge between the corresponding nodes was added. 
We aimed to identify the set of nodes that maximized the sum of the weights (reliability 
scores) when no pair of nodes was evolutionarily incompatible.  This maximal set 
represents the most reliable and evolutionarily compatible mutation patterns 
(Supplementary Information). We modeled and solved the maximization challenge using 
a Mixed Integer Linear Program38 (MILP; see Online Methods). Additionally, we proved 
via a reduction to the weighted minimum vertex cover problem that the decision version 
of finding the most reliable and evolutionarily compatible mutation patterns is 
NP-complete43 (see Supplementary Information for mathematical proofs). 
 
Predicting putative artifacts in sequencing data 
The solution obtained with the MILP provided the most likely evolutionarily compatible 
mutation pattern for each variant. By comparing our inferred classifications to 
conventional binary classification, Treeomics predicted putative sequencing or biological 
artifacts in the data (Fig. 2). The conventional classifications differed in 8.8% of the 
variants in Pam03 (78 putative artifacts from 89 variants in 10 samples; Fig. 2). As 
expected, the majority (72) of the differences were caused by putative false-negatives in 
the binary classification that were inferred to be present by Treeomics (Table 1). 
Fifty-nine of these putative false-negatives had relatively low coverage, explaining how 
they could easily be misclassified as absent given the low neoplastic cell content in these 
samples. Accordingly, many of these under-powered false-negatives occurred in samples 
with the lowest coverage (LiM 5, LuM 2-3) or lowest neoplastic cell content (LuM 1). In 
LuM 2, the driver gene mutation KRAS was incorrectly classified as absent by 
conventional means though it is most likely a clonal founding mutation and was present 
at a VAF of 19% in the original WGS sample (Supplementary Table S1). Some variants 
contained false-negatives across many samples, indicating that these variants were 
generally difficult to call. Remarkably, 95% (56/59) of the predicted under-powered 
false-negatives were either significantly present in the WGS data (mostly at higher 
coverage than in the targeted sequencing data), or the genomic region of the variant 
possessed a low alignability score (Supplementary Table S1).  
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An additional 13 putative false-negatives were sequenced at relatively high 
coverage, but might be explained by loss of heterozygosity (LOH), which frequently 
occurs in pancreatic cancers. Of the 6 putative false-positives (purple squares in Fig. 2b; 
e.g., abParts, MFN1), 83% (5/6) were classified as absent in the original WGS data and 
all of them were in a genomic region with a low alignability score44,45 (Supplementary 
Table S1). Hence, at least 6.9% (56 putative false-negatives + 5 putative false-positives) 
of the variants were misclassified by conventional binary classification. If a 
phylogenomic method does not account for sequencing artifacts, a large fraction of 
variants will often be inconsistent with any inferred evolutionary tree. In our case, at least 
31.5% of the variants would be evolutionarily incompatible – independent of the inferred 
tree topology (Fig. 2a). These putative artifacts may also help to explain the observed 
high tumor heterogeneity in earlier studies and the recently reported tumor homogeneity 
when sequencing depth is increased22,28. 
 
Inferring evolutionary trees 
From the identified mutation patterns, Treeomics inferred an evolutionary tree rooted at 
the germline DNA sequence of Pam03 (Fig. 3). We found strong support for two major 
evolutionary clusters among the geographically distinct lesions: (i) samples LiM 2-5 
(liver mets) and PT 11 (primary tumor) and (ii) samples LiM 1, LuM 1 (lung met.) and 
PT 10. These results indicate that a recent parental clone of PT 11 seeded the liver 
metastases in cluster (i) and a recent parental clone of PT 10 seeded the lung and liver 
metastases in cluster (ii); perhaps the same clone also seeded LuM 2 and 3, however, the 
low neoplastic cell content and the low coverage of LuM 2 and 3 prevented a definite 
conclusion. We also reconstructed the same major clusters by using the low-coverage 
WGS data (Fig. S4) instead of the high coverage targeted sequencing data (Fig. 3). The 
inferred trees indicated that the lung metastases had been seeded before most of the liver 
metastases in patient Pam03 (Fig. 3). Furthermore, the results suggested that the liver 
metastasis LiM 1 was seeded from a genetically different subclone than all other liver 
metastases.  In a different treatment-naïve pancreatic cancer patient (Pam02) we also 
found that liver metastases diverged late in the inferred evolutionary tree (Fig. S5). 
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Confirming robustness of the identified mutation patterns 
We investigated the robustness of our results by determining whether Treeomics could 
identify the inferred mutation patterns and their evolutionary trajectories from a random 
subset of the given variants. Through this analysis, we found that only  ~two thirds of the 
variants in Pam03 were sufficient to identify all major evolutionary relationships and 
clusters, despite the fact that only 34% of variants were identified as 
parsimony-informative (Fig. S6a). As expected, subclusters within the main clusters were 
less frequently reproduced as indicated by the lower bootstrapping values because of 
inadequate supporting sequencing data. 
 
To further validate our approach, we reanalyzed data from high-grade serous 
ovarian cancers23. We were able to reproduce all phylogenetic trees of Bashashati et al.23 
except for Case 5. In this case, the authors reported an early divergence of sample 5c 
while Treeomics suggested a late divergence (Fig. S7c). Comprehensive analysis of their 
data (reinterpreted in Fig. S7a,b) revealed that their tree either required that several 
variants (including two driver gene mutations and multiple indels) occurred 
independently twice or that two mutations in the driver genes ABL1 and MDM4 were 
lost; both possibilities seem implausible (Fig. S7 and Fig. 1D in ref. 23).  Treeomics did 
not require these implausible scenarios to construct an otherwise similar tree.  We 
confirmed the robustness of our results via bootstrapping (Fig. S6b). Distance-based 
methods, such as those used by Bashashati et al., can be compromised by large 
differences in the number of acquired mutations among samples; sample 5c had twice as 
many mutations than most other samples.   
 
We also reanalyzed a comprehensive data set from prostate cancers21. Treeomics 
generally confirmed the results and further refined others. For example, for patient A32, 
Gundem et al. (2015) reported an inconclusive evolutionary tree due to evolutionary 
incompatible subclones present at low frequencies. Our method used the strong evidence 
for mutation patterns C, E and D, F (see Extended Data Figure 3p,q in ref. 21) and was 
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thereby able to illuminate the evolutionary relationships among these samples in a 
conclusive fashion (Fig. S8). 
 
Detecting subclones of distinct origin 
If multiple subclones were represented in the same sample, conventional phylogenetic 
approaches would be unable to separate their evolutionary trajectories. In the cases where 
multiple subclones present at low frequencies were apparent, evolutionarily incompatible 
mutation patterns with high reliability scores were identified (Fig. S9b). By investigating 
the VAFs of the variants in these patterns, we could infer separate evolutionary histories 
for the subclones (Online Methods). For both the prostate cancer data of case A2221 
(Fig. S9) and of case 620 (Fig. S10), Treeomics identified subclonal structures and 
separated their evolutionary trajectories without requiring high purity samples or deep 
sequencing data as are required by previously used methods.  
 
DISCUSSION 
The new approach described here efficiently reconstructs the evolutionary history, detects 
potential artifacts in noisy sequencing data, and finds subclones of distinct origin. The 
evolutionary theory of asexually evolving populations combined with Bayesian inference 
and Integer Linear Programming enabled us to infer detailed phylogenomic trees. In 
contrast to other tools, Treeomics accounts for putative artifacts in sequencing data and 
can thereby infer the branches where somatic variants were acquired as well as where 
some may have been lost during evolution, presumably through losses of heterozygosity 
resulting from chromosomal instability46. The branching in the inferred trees sheds light 
on the seeding patterns (timing47 and location) of particular metastatic lesions11,12.  
 
We have designed Treeomics from first principles to directly handle ambiguity in 
high-throughput sequencing data, including samples with low neoplastic cell content or 
coverage. The mutation patterns and their evolutionary conflict graph form a robust data 
structure and consequently the painful task of semi-automatic filtering becomes 
unnecessary. As a result of the Bayesian confidence estimates for the individual variants, 
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this method can infer more robust results than traditional phylogenetic methods, which 
employ a binary representation of sequencing data. Furthermore, as shown above, 
distance-based methods can produce results inconsistent with the evolutionary theory of 
cancer as they often ignore knowledge of biological phenomena specific to neoplasia 
(Fig. S7). We compared our results to another state-of-the-art method in cancer 
phylogenomics37 (other methods were not applicable for multiple spatially-distinct 
samples with low neoplastic cell content). AncesTree37 roughly identified one of the 
major evolutionary clusters in Pam03 but excluded 58% (37/89) of the variants (among 
them the driver gene mutation in KRAS) in the inferred phylogeny due to evolutionary 
incompatibilities (Fig. S11).  
 
At present Treeomics only employs nucleotide substitutions and short insertions 
and deletions – a subset of the available information. Other types of data, such as copy 
number alterations, structural variations and DNA methylation, could be incorporated 
into Treeomics to further improve the accuracy of the inferred results48–51. Such analyses 
can benefit from analyzing all tumor samples from the same patient together (plus a 
matched normal sample) to account for the joint evolution of cancer cells, yielding more 
robust results52. 
 
The challenge in finding the most likely evolutionary trajectories is NP-complete. 
However, medium-sized instances of NP-complete problems are no longer intractable 
due to the enormous engineering and research effort that has been devoted to ILP solvers. 
The MILP formulation enables an efficient and robust analysis of large datasets (see 
Supplementary Information, Theorem 1, for more details about the theoretical limits). 
MILPs may also be useful in other areas of phylogenetic inference where methods with 
strong biological assumptions (e.g. constant mutation rates or specific substitution 
profiles) are not applicable or are computationally too expensive to obtain guaranteed 
optimal solutions. 
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ONLINE METHODS 
 
DNA sequencing design and validation 
As described in detail in ref. 22, sequencing data were generated in two stages. First, 
genomic DNA from 22 tumor samples (16 metastases and 6 primary tumor sections) was 
evaluated by 60x whole genome sequencing (WGS) using an Illumina Hi-Seq 2000. 
Importantly, genomic DNA from the normal tissues of each patient was used to facilitate 
identification of somatic variants. We obtained an average coverage of 69x with 97.5% of 
bases covered at >10x, revealing a total of 106,919 putative coding and noncoding 
somatic mutations, (average of 4,860 per sample). To limit the artifacts generated by 
WGS and alignment, we filtered the putative variants using several quality parameters, 
including read directionality, mutant allele frequency detected in the normal, known 
human SNPs, and the number of independent tags at each site. 
 
Second, we utilized a targeted sequencing approach to independently screen every 
mutation that we observed to be of high quality in at least one WGS tumor sample. 
Briefly, probes for capture were designed to flank each potential mutant base (n = 960) 
and libraries were prepared for the original 22 WGS samples. Using an Illumina chip-
based approach, we successfully aligned, processed, and validated 219 mutations (range 
107-112 per patient) at an average sequencing depth of 772x (Supplementary Tables S2 
and S3). In addition to the increased coverage and sensitivity of targeted sequencing, both 
sequencing approaches generated independent datasets in which we could directly 
compare putative variants in silico among many tumors within a patient. Additional 
details regarding patient selection, processing of tissue samples and DNA extraction and 
quantification can be found in ref. 22. 
 
Bayesian inference model 
To compute reliability scores for each mutation pattern, we first extract posterior 
probabilities for the presence and absence of a variant in a sample from a Bayesian model 
of error-prone sequencing. If f is the true fraction of variant reads in the sample, ! is our 
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prior belief about f, and e is the sequencing error rate, the posterior distribution ! of f 
given N total reads and K variant reads is  ! ! !,! = !! ∙ ! 1− ! + 1− ! ! ! ∙ ! ∙ ! + 1− ! 1− ! !!! ∙ ! ! ∙ 1! (1) 
where ! is a normalizing constant (see Supplementary Information). A priori, the variant 
allele frequency in a sample is exactly zero (! = 0) with some positive probability !!. 
The prior ! is then of the following form  ! ! = !! ∙ ! ! + 1− !! ∙ ! ! , (2) 
where ! !  denotes the Dirac delta function and !(!) denotes a prior given the variant is 
present (Supplementary Information). The prior can differ for each variant to account for 
sample purity and variant ploidy. The probability that a variant is absent, denoted by !, 
and the probability that a variant is present, denoted by !, are  ! = ! ! = 0 !,! , !  = 1− !. (3) 
A variety of more sophisticated variant detection algorithms can be used here as long as 
the output can be converted to posterior probabilities of presence and absence. We 
calculate the probability of each mutation pattern for a particular variant by multiplying 
the corresponding posterior probabilities for each sample. Each mutation pattern has 
some positive probability, but those supported by the data are given much more weight. 
A mutation pattern ! is denoted as a binary vector of length |!| (total number of samples) 
where !!  is 1 if the variant is present in sample ! and 0 if absent. The likelihood !! !  that a variant ! exhibits pattern ! is !!(!) = !!,!!! ∙ !!,!!!!! .!∈!  (4) 
The reliability score !!  of each mutation pattern ! (corresponding to a node in the 
evolutionary conflict graph; Fig. S3) is given by  !! = −!"# 1− !! !! . (5) 
The argument of the logarithm denotes the probability that no mutation has pattern ! and 
hence leverages the full sequencing information from all variants. With these scores 
(weights), the minimum weight vertex cover of the evolutionary conflict graph 
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corresponds to identifying the most reliable and evolutionarily compatible mutation 
patterns (see Supplementary Information for further details). 
Identifying reliable evolutionarily compatible mutation patterns 
Given the calculated reliability scores, we efficiently find the most reliable and 
evolutionarily compatible mutation pattern for all variants via solving a mixed integer 
linear program38 (MILP). In the Supplementary Information we prove that finding these 
mutation patterns is equivalent to solving the Minimum Vertex Cover problem; one of 
Karp's original 21 NP-complete problems43. In the Minimum Vertex Cover problem one 
wants to find the minimum set of nodes in an undirected graph such that each edge in the 
graph is adjacent to one of the nodes in the minimum set. Therefore, by definition all 
edges are covered by the nodes in the minimum set. Similarly, we try to find the weighted 
set of nodes (here mutation patterns) with the minimal sum of reliability scores such that 
no evolutionary incompatibilities in the conflict graph remain. After this minimal set of 
nodes and their adjacent edges have been removed from the graph, we can easily infer an 
evolutionary tree since evolutionary conflicts no longer exist (i.e., all edges were covered 
and removed with the minimal set). The remaining set of mutation patterns is by 
definition the maximal set of evolutionarily compatible patterns (see Supplementary 
Information for details). 
 
In the evolutionary conflict graph ! = (!,!) , each node ! ∈ !  represents a 
different mutation pattern. For ! samples, the number of nodes |!| is given by 2!. For 
each pair of evolutionarily incompatible mutation patterns ! and !, there exists an edge (!, !) ∈ !. The weight (!!) of each node ! is given by the reliability scores !! described in 
the Bayesian inference model section (Fig. S3). 
 
The MILP to find the minimal-weighted set of evolutionarily incompatible mutation 
patterns is defined by the following objective function and constraints:  
(objective function) minimize  !! ∙ !!!∈!   (6) 
(constraints) 
subject to  !! + !! ≥ 1 
             !! ∈ {0,1}, !! > 0 for all (!, !) ∈ ! for all ! ∈ !  
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This formulation guarantees that the MILP solver finds the minimal value of the 
objective function such that all constraints are met and hence the nodes in the selected set 
cover all edges. The evolutionarily compatible and most reliable mutation 
patterns {! | !! = 0} are given by the complement set of the optimal solution {! | !! = 1} 
to the MILP. 
 
Inferring evolutionary trees 
After the evolutionarily compatible mutation patterns {! | !! = 1} have been identified 
and variants are assigned to their most likely evolutionarily compatible pattern based on 
the maximum likelihood weights given by the Bayesian inference model, the derivation 
of an evolutionary tree is a trivial computational task. In quadratic time (!(! ∙!)) of the 
input size we construct a unique phylogeny where ! is the number of samples and ! is 
the total number of distinct variants53. The branches where the individual variants are 
acquired follow from the inferred tree.  
 
Detecting subclones of distinct origin 
Evolutionary incompatible mutation patterns with high reliability scores may indicate 
mixed subclones with distinct evolutionary trajectories (Fig. S9b, Fig. S10a). Recall that 
evolutionary incompatibility requires that the conflicting variants need to be present 
together in at least one sample. However, even if both variants are mutated in a 
statistically significant fraction in the same sample, these variants may not be present in 
the same cells and the evolutionary laws of an asexually evolving population may not be 
violated. If low VAFs of those variants support this hypothesis, Treeomics updates the 
corresponding mutation patterns and infers distinct evolutionary trajectories to these 
subclones. Low VAFs of the variants in descending (not necessarily evolutionary 
incompatible) mutation patterns of the putative subclone provide additional evidence for 
mixed subclones in a sample. As outlined for prostate cancer case A22, subsets 
(descendants) and supersets (ancestors) of the conflicting mutation pattern can 
simultaneously be identified and a comprehensive evolutionary tree inferred (Fig. S9c). 
This approach also worked well among samples from the same tissue. After two 
subclones were separated, 12643 (out of 12645) variants supported the inferred 
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evolutionary tree (Fig. S10b). The remaining two variants were predicted to be 
false-positives by Treeomics.  
Binary present/absent classification 
We perform conventional binary present/absent classification of each variant to allow a 
comparison to the inferred classification used in our new approach. We scored each 
variant by calculating a p-value in all samples (one-tailed binomial test): Pr ! ≥ ! !!,!,! = 1− !! ∙ !!"#!!!!!!! ∙ (1− !!"#)!!!  where N denotes the 
coverage, K denotes the number of variant reads observed at this position, and X denotes 
the random number of false-positives. As null hypothesis H0, we assume that the variant 
is absent. Similar to Gundem et al.21, we assumed a false-positive rate (pfpr) of 0.5% for 
the Illumina chip-based targeted deep sequencing. In the WGS data set we assumed a 
conservative false-positive rate of 1%54. We used the step-up method55 to control for an 
average false discovery rate (FDR) of 5% in the combined set of p-values from all 
samples of a patient. Variants with a rejected null hypothesis were classified as present.  
The remaining variants were classified as absent.  
 
Treeomics 
The source code and manual for Treeomics, as well as multiple examples illustrating its 
usage, are provided at https://github.com/johannesreiter/treeomics. The tool is 
implemented in Python 3.4. The inputs to the tool are the called variants and the 
corresponding sequencing data, either in tab-separated-values format or as matched 
tumor-normal VCF files. As output, Treeomics produces a comprehensive HTML report 
(Supplementary File 1) including statistical analysis of the data, a mutation table plot and 
a list of putative artifacts (false-positives, well-powered and under-powered 
false-negatives). Additionally, Treeomics produces evolutionary trees in LaTeX/TikZ 
format for high-resolution plots in PDF format. If circos56 is installed, Treeomics 
automatically creates the evolutionary conflict graph and adds it to the HTML report. 
Treeomics also supports various filtering (e.g., minimal sample median coverage, false-
positive rate, false-discovery rate) for an extensive analysis of the sequencing data. 
Detailed instructions for the filtering and analysis are provided in the readme file in the 
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online repository. For solving the MILP, Treeomics makes use of the common CPLEX 
solver (v12.6) from IBM. 
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FIGURE LEGENDS 
Fig. 1:  Observed tumor heterogeneity across lesions of pancreatic cancer patient 
Pam03. Each variant found in any lesion is shown and its chromosomal position 
indicated in the outermost circle. Parsimony-informative variants (black dots; black 
gene names) are present in more than one but not in all samples and can provoke 
evolutionary incompatibilities. Founder variants (present in all samples; green squares; 
green gene names) and unique variants (present in a single sample; blue triangles; blue 
gene names) are parsimony-uninformative. The five innermost circles correspond to 
samples from five distinct liver metastases (LiM 1-5); the following three circles 
correspond to samples from three distinct lung metastases (LuM 1-3); the other circles 
correspond to different parts of the primary tumor (PT 10-11). 
Fig. 2:  Treeomics identifies evolutionarily compatible mutation patterns after 
recognizing potentially misleading artifacts in the sequencing data. Variants 
shown in Fig. 1 are organized as evolutionarily-defined groups (“nodes”) rather than 
by chromosomal positions. The nodes are indicated in the outermost circle: blue 
colored nodes are evolutionarily compatible and red colored nodes are evolutionarily 
incompatible. a | Based on conventional present/absent classification, at least 31.5% of 
the variants were evolutionarily incompatible (depending on the inferred tree 
topology). The incompatibilities are demarcated by red lines (“edges”) in the center of 
the circle that connect each pair of incompatible nodes. b | Based on a Bayesian 
inference model and a Mixed Integer Linear Program, Treeomics identified the most 
likely evolutionarily compatible mutation pattern for each variant (Online Methods). 
This method predicted that 8.8% (78/890) variants across all samples were 
misclassified and thereby caused the evolutionary incompatibilities shown in panel a. 
Putative false-negatives with low coverage sequencing data are depicted by unfilled 
purple triangles. Powered (coverage above 100) putative false-negatives are depicted 
by filled purple triangles. Putative false-positives are depicted by purple squares. The 
driver gene mutation in KRAS was among the putative false-negatives in one of the 
ten lesions.  
Fig. 3:  Reconstructed evolution of patient Pam03's cancer from targeted 
sequencing data. Lung metastases (LuM 1-3) are depicted in red; Liver metastases 
(LiM 1-5) are depicted in green; Primary tumor samples (PT 10-11) are depicted in 
black. SC indicate predicted subclones. Gray percentages indicate bootstrapping 
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values from 1000 samples. Based on the identified evolutionarily compatible mutation 
patterns in Fig. 2b, a unique evolutionary tree exists. LiM 1 was seeded from a 
different subclone than all other liver metastases. Due to the limited number of 
targeted resequenced variants, the support for some branches was relatively low, in 
particular within the identified main clusters (e.g. LiM 2-5). The majority of variants 
(55%) were already present in the founding clone.  
 
TABLES 
Table 1. Treeomics predicted putative artifacts in ten sequencing samples of 
pancreatic cancer patient Pam03. Many putative false-negatives with low statistical 
power occurred in samples with the lowest coverage (LiM 5, LuM 2-3) or lowest 
neoplastic cell content (LuM 1). Five distinct liver metastases (LiM 1-5), three distinct 
lung metastases (LuM 1-3), two different parts of the primary tumor (PT 10, 11). 
Artifact type LiM 1 LiM 2 LiM 3 LiM 4 LiM 5 LuM 1 LuM 2 LuM 3 PT 10 PT 11 Total 
Under-powered 
false-negatives 
7 2 5 1 13 12 5 5 1 8 59 
Powered  
false-negatives 
2 2 2 2 1 1 0 0 1 2 13 
False-positives 0 1 0 0 0 3 0 1 0 1 6 
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